Table 2 Differences in baseline characteristics between survivors and non-survivors
Survivors (n = 90) | Non-survivors (n = 76) | p-value | |
|---|---|---|---|
Infection site (n, %) | |||
Hospital-acquired pneumonia | 27 (30.0) | 24 (31.6) | 1.00 |
Primary bacteremia | 13 (14.4) | 17 (22.4) | 0.226 |
Intrabdominal infection | 14 (16.9) | 21 (25.3) | 0.253 |
Community-acquired pneumonia | 12 (13.3) | 12 (15.8) | 0.665 |
Acute pyelonephritis | 6 (6.7) | 2 (2.6) | 0.291 |
Acute bacterial skin and soft tissue infection | 4 (4.4) | 0 (0) | 0.126 |
Bacterial meningitis | 2 (2.2) | 0 (0) | 0.501 |
Other | 3 (3.3) | 0 (0) | 0.251 |
Organ dysfunction (n, %) | |||
Septic shock | 52 (57.8) | 60 (78.9) | 0.005 |
Acute respiratory distress syndrome | 43 (47.8) | 47 (61.8) | 0.086 |
Acute kidney injury | 12 (13.3) | 22 (28.9) | 0.020 |
Disseminated intravascular coagulation | 17 (18.9) | 22 (28.9) | 0.144 |
Co-morbidities (n, %) | |||
Type 2 diabetes mellitus | 21 (23.3) | 17 (22.4) | 1.00 |
Chronic heart failure | 21 (23.3) | 20 (26.3) | 0.719 |
Chronic obstructive pulmonary disease | 16 (17.8) | 18 (23.7) | 0.440 |
Chronic renal disease | 9 (10.0) | 8 (10.5) | 1.00 |
Coronary heart disease | 18 (20.0) | 5 (6.6) | 0.014 |
Vascular hypertension | 23 (25.6) | 16 (21.1) | 0.583 |
Atrial fibrillation | 11 (12.2) | 6 (7.9) | 0.445 |
Stroke | 12 (13.3) | 11 (14.5) | 1.00 |
History of stage I/II solid malignancy | 38 (42.2) | 45 (59.2) | 0.043 |